Polymath Investor — Slow and Steady Wins the Race: BioSyent (Jul 2026)

One-line take: A Canadian TSXV microcap that never invents a drug — it in-licenses proven products from others and sells them through a small Canadian sales force, which means no research risk and no patent cliff, only execution risk. That formula has produced 63 consecutive profitable quarters and 14-year compound growth of 19.6% revenue / 17.7% EPS with the share count down 20%. The reason the authors are writing it up now: the story is no longer one product. FeraMAX, Canada's most-recommended iron supplement for eleven straight years, has gone from ~70% of revenue to closer to 40%, diluted by two new pillars — the March 2026 $25.5M acquisition of Oral Science (a dental-hygiene distributor into >6,000 clinics, ~40% of Canada's dental clinics; $31.2M of 2025 revenue compounding at 15%, bought at 6.3× TTM EBITDA and under 5× adjusted for working capital) and Thyconvi, Canada's first liquid levothyroxine, in-licensed for an upfront fee of EUR 50,000 and approved by Health Canada in May 2026. Only one month of Oral Science ($2.98M) has printed inside BioSyent's reported numbers so far. Thyconvi is underwritten conservatively — management's base case assumes zero provincial reimbursement (the formulary discount is judged uneconomic) and guides to a $10M peak year over 5+ years; the authors model a wider $5–20M range off IQVIA data and international liquid-levothyroxine analogues. CEO René Goehrum owns ~20%; an investor who bought when he took the helm in 1999 at ~$0.20 would be up 72×. Valuation: ~8.5× 2027E EV/EBITDA against a re-rate target of 10–12×, for a base-case fair value of $22–30 vs. $14.50 today. Biggest watch-point: Accrufer (Kye Pharmaceuticals), Canada's first and only prescription oral iron — prescription status unlocks provincial drug-plan coverage that FeraMAX, classified as a natural health product, structurally cannot access. Also: Oral Science integration/key-person risk (founder Daniel Ménard) and Curaden distribution dependency, and a stock that trades a median ~5,000 shares a day. Disclosure: Forterra holds RX in managed accounts, both authors hold it personally, and neither will transact for ten business days after publication.

1. Stocks & names mentioned

Ticker	Name	Research	View	What they said	Source
RX.V	BioSyent	QT · SA · STK	Positive	The whole post. A Canadian specialty pharma that in-licenses rather than discovers — "no research risk and no patent cliff," turning "almost entirely on commercial execution," a formula that has produced 63 consecutive profitable quarters. At $14.50 / $167M market cap. The core argument is that concentration risk has been engineered away: FeraMAX (Canada's leading recommended iron supplement eleven years running) fell from ~70% of revenue to ~40% as two new pillars arrived — Oral Science, bought March 2026 for $25.5M at 6.3× TTM EBITDA (<5× adjusted for working capital), distributing into >6,000 dental clinics (~40% of Canada's), $31.2M of 2025 revenue compounding at 15%, guided to ~$30M over the ten months of 2026 ownership with 10–12% organic growth assumed, of which only one month ($2.98M, March 2026) has printed inside BioSyent's numbers; and Thyconvi, Canada's first liquid levothyroxine, in-licensed for an EUR 50,000 upfront and Health Canada-approved May 2026 — "one of the company's most asymmetric bets." Track record over 14 years: revenue +19.6% CAGR, net income +15.9%, EPS +17.7%, share count −20%, dividend rising and buybacks continuing through the acquisition. CEO René Goehrum owns ~20% ("that alignment is a large part of why capital allocation has been this disciplined"); the stock is a 72-bagger since he took over in 1999 at ~$0.20. Free optionality: PerioMonitor (a chairside gingivitis diagnostic already US-approved, actively being out-licensed, with a capped royalty back to Oral Science's seller — "we would not be surprised to see a global out-licensing deal … within the next twelve months"), provincial formulary access on Thyconvi (excluded from the base case entirely), further acquisitions, and FeraMAX line extensions. Valuation: ~8.5× 2027E EV/EBITDA against 18% EPS and 24% adj-EBITDA CAGRs 2025–28, re-rating to 10–12× for a base-case fair value of $22–30. Risks, ranked: Accrufer — the first and only prescription oral iron in Canada, whose prescription status is "a structural advantage over FeraMAX's classification as a natural health product" because it unlocks provincial formulary and drug-plan coverage FeraMAX cannot access (evidence to date says it is drawing new patients, not switchers, and FeraMAX still grew through 2025, but "this remains the single largest watch-point for our thesis"); Thyconvi execution; Oral Science integration, founder key-person risk and Curaden distribution dependency; and thin liquidity (~5,000 shares a day median, one sell-side analyst) which "cuts both ways — it is part of why we believe the opportunity exists at all." Held by Forterra and both authors; no transactions for ten business days post-publication.	read ↗

Row id uses the Yahoo/TSX-Venture symbol RX.V — bare "RX" collides with US listings, so the suffixed form keeps prices, exchange and auto-links pointing at BioSyent. QT/SA point at the OTC symbol BIOYF (BioSyent's US OTC Pink line); STK uses the TSXV quote page. Research: QT Qualtrim · SA Seeking Alpha · STK Stock Analysis. The "Source" link opens the post (no per-name timestamps — it's a written piece). Named but not given rows (no investable line for this archive): Oral Science (acquired March 2026 — now a BioSyent subsidiary, not a separate security), Kye Pharmaceuticals (private; the Accrufer competitor, cited only as the risk), Curaden (private Swiss distribution partner), Forterra Investment Management (the co-author's firm, not a listed vehicle), and the product/brand names FeraMAX, Thyconvi, Tibella, Tibelia, PerioMonitor, Hedley Technologies.

2. Talking points

The business model: license, don't discover

"BioSyent does not discover drugs. It licenses them, which means the business carries no research risk and no patent cliff, and turns almost entirely on commercial execution." Through BioSyent Pharma it identifies underserved therapeutic niches, in-licenses or acquires products with genuine clinical differentiation, and sells them through a small, focused Canadian sales force.
The output of that formula: 63 consecutive profitable quarters — a run that starts long before any of the current growth pillars existed.
Roots in Hedley Technologies, a legacy biological insecticide business that still throws off modest, lumpy revenue; renamed BioSyent in 2006 on the pivot to pharmaceuticals, built mainly around women's health sold into pharmacies, hospitals and specialists in Canada.

The concentration problem — and how it got fixed

FeraMAX has been Canada's leading recommended iron supplement for the eleventh consecutive year and, until recently, was ~70% of revenue. A single-product company priced as one.
Two moves in 18 months took that to ~40%: the Thyconvi launch and the March 2026 acquisition of Oral Science for $25.5M. "This is a more diversified and more resilient business than it was even two years ago."
2025 segment split: pharmaceutical sales $40.9M (95% of total); Oral Science ~$31.2M standalone (not yet consolidated for the full year); legacy insecticide treated as "a residual cash flow stream."

Oral Science — the catalyst hiding in plain sight

"This may be the most underappreciated part of the current setup." Reported results include only a single month of Oral Science — $2.98M of revenue in March 2026. Investors have not yet seen a full quarter inside the numbers, let alone a full year.
Distribution into >6,000 Canadian dental clinics, close to 40% of the clinics in the country, plus retail pharmacy and direct-to-consumer. Roughly a third of revenue from proprietary products, the balance from exclusive distribution agreements with international partners. Historic compounding: 15%.
Price paid: 6.3× trailing-twelve-month EBITDA, and under 5× after adjusting for working capital — "a highly accretive multiple for a quality business growing at double digits." Management guides ~$30M of revenue over the ten months of 2026 ownership; the authors' base case assumes 10–12% organic growth from air-polisher penetration (early in its adoption curve) and a push into dental service organizations.

Thyconvi — a EUR 50,000 option on a $5–20M product

Licensed in mid-2024 for an upfront fee of just EUR 50,000; management calls it "one of the company's most asymmetric bets, with negligible capital at risk." Health Canada approval landed May 2026, and it is now in commercial launch.
The product gap is real: levothyroxine tablets have been generic for decades, but no liquid alternative has existed in Canada — a genuine problem for patients with swallowing difficulties (~2.5% of the population, "a larger group than most investors would guess"), paediatric patients, and anyone whose absorption issues make tablet dosing unreliable.
Underwriting discipline: management's base case assumes no contribution at all from provincial reimbursement, on the view that the discount needed to win formulary listing would be uneconomic — the whole plan is built on private pay, with private-insurance filings on a wide-open label. Management guides a $10M peak year that could take 5+ years; the authors' own IQVIA-plus-international-analogue work points to $5–20M. "We do not believe the market is giving BioSyent any credit for what Thyconvi can contribute over the next three to five years."

Capital allocation and owner-operator alignment

Raising the dividend and repurchasing stock while absorbing the largest acquisition in company history, with the balance sheet already rebuilding cash post-deal — and an acquisition opportunity set management says now spans oral health and further endocrinology assets alongside the pharmaceutical base.
14-year compounding: revenue +19.6%, net income after tax +15.9%, EPS +17.7% — with the share count down 20% over the same stretch. Strong operating margins, impressive ROIC.
CEO René Goehrum owns ~20% of the shares. "We think that alignment is a large part of why capital allocation has been this disciplined." Buy at $0.20 when he took the helm in 1999 and you'd have made more than 72× your money.

Optionality the base case doesn't pay for

PerioMonitor — Oral Science's chairside gingivitis diagnostic returning results in minutes at a fraction of the cost of lab-based swab-and-send. Already US-approved; management is actively seeking to out-license it outside Canada. "The potential is genuinely hard to size today, which is precisely why Oral Science structured the sale to BioSyent to include a royalty on it" — capped, with margins still very strong after royalties. A global out-licensing deal within twelve months "would not surprise us."
Thyconvi upside — because the case assumes no public reimbursement, any provincial formulary access is pure upside, as is any outcome toward the top of the $5–20M range.
Further M&A — balance-sheet capacity plus stated interest across oral health and endocrinology makes another deal plausible, "though we do not build one into our base case." Plus FeraMAX line extensions, including what the authors believe is an iron combination product.

Risk #1: Accrufer and the natural-health-product ceiling

Accrufer (ferric maltol), launched by Kye Pharmaceuticals in early 2025, is the first and only prescription oral iron product in Canada. "Prescription status is a structural advantage over FeraMAX's classification as a natural health product, because it opens the door to provincial formulary and drug plan coverage that FeraMAX cannot access."
Off to a strong start with "a real commercial base — enough to matter against a franchise the size of FeraMAX, though still a small fraction of it." Mitigants: FeraMAX kept growing through 2025, the evidence suggests Accrufer is drawing new patients rather than switchers, and the overall iron market is expanding.
Nonetheless: "this remains the single largest watch-point for our thesis."

The other risks: execution, integration, liquidity

Thyconvi: reimbursement filings, physician adoption curves and peak-sales timing are all unproven — "our $5 million to $20 million range is wide for a reason."
Oral Science: a newly acquired business with key-person considerations around founder Daniel Ménard and distribution-partner concentration, including a Curaden relationship working through a leadership transition after its founder's death in mid-2025.
Liquidity and information asymmetry: one sell-side analyst, thin average daily dollar volume, a median ~5,000 shares a day. "This cuts both ways. It is part of why we believe the opportunity exists at all, but it also means the shares can move sharply on light news flow, and that building or exiting a position of size requires patience."

Valuation: 8.5× today, 10–12× if it executes

Trades at roughly 8.5× 2027E EV/EBITDA. Base case: EPS compounding 18% and adjusted EBITDA 24% from 2025 to 2028, most of the increase from Oral Science.
What that requires is unremarkable: mid-single-digit growth in pharmaceutical sales, a modest Thyconvi contribution in 2027–28, and 12% growth in oral health. "This requires strong execution, but it does not require anything exceptional."
If delivered, the business "should be valued at 10 to 12 times EV/EBITDA" — a base-case fair value range of $22 to $30 per share against $14.50, wide because it looks out three years. Thyconvi, PerioMonitor or another acquisition landing well could push beyond the top end.

Why it's insulated, and why the market missed it

"The market was not paying much attention to it while the story depended so heavily on FeraMAX, and we were in that camp for some time despite having the company on our watchlist." The change is that it is "no longer a one-trick pony."
Macro-indifference is part of the appeal: "Whatever happens with international conflict, the oil price, inflation, consumer credit and trade wars, a business like BioSyent is largely insulated. The success driver here is execution."
Explicitly not a short-term case: "The investment case will not play out in the short term. That is fine by us." Understanding a larger business takes time, "but we expect the results will eventually be hard to ignore."

3. In plain English

A jargon-free summary of the thesis. (Plain-language companion to the table above; renders on the ticker's consolidated page.)

RX.V — BioSyent Positive

BioSyent is a small Canadian drug company — about $167 million in total value, share price $14.50 — that does something unusual: it never invents anything. Inventing a drug costs hundreds of millions and usually fails; and when it works, the patent eventually expires and generic copies destroy the profits (drug people call that the "patent cliff"). BioSyent skips both problems by doing what's called in-licensing: it finds a product that someone else already developed and got approved — usually in Europe — and buys the right to sell it in Canada, then sells it through its own small sales team of reps who visit pharmacies, hospitals and specialist doctors. No laboratory, no research gamble, no cliff. The only thing that can go wrong is bad selling. It has now been profitable for 63 quarters in a row — nearly sixteen straight years.

Until recently the company was really one product: FeraMAX, an iron supplement, which Canadian pharmacists have recommended more than any other for eleven years running and which was about 70% of all revenue. That is a dangerous amount of eggs in one basket, and it is why, the authors argue, nobody paid attention to the stock. Two things changed that in eighteen months. In March 2026 BioSyent bought Oral Science, a dental-hygiene supplier, for $25.5 million; it sells into more than 6,000 dental clinics — roughly four in every ten in Canada — and did $31.2 million of revenue last year, growing 15% a year. The price paid was 6.3 times the target's annual operating profit (and under 5 times once you account for the inventory and receivables that came with it), which for a business growing at double digits is cheap. And in May 2026 Health Canada approved Thyconvi, the first liquid version of levothyroxine — the standard thyroid medicine — available in Canada. Between them, FeraMAX has dropped to about 40% of revenue. Same company, far less fragile.

The Thyconvi story is the clearest illustration of how this management team thinks. The rights cost an upfront fee of 50,000 euros — a rounding error — for a product addressing one of Canada's biggest chronic prescription categories. Tablets have been around for decades, but some patients genuinely cannot use them: people who struggle to swallow (about 2.5% of the population), children, and people whose bodies absorb tablets inconsistently. Management thinks it could eventually reach $10 million of annual sales; the authors think $5–20 million. And here is the discipline that matters: the plan assumes provincial governments never pay for it at all. To get on a province's approved-drug list you must offer a steep discount, and management decided that isn't worth it — so the whole forecast is built on patients and private insurers paying directly. Any government coverage that does happen is a free bonus on top.

Two more things the authors like. First, alignment: the CEO, René Goehrum, personally owns about a fifth of the company — so when he decides whether to raise the dividend, buy back shares or do a deal, he is spending his own money. Over 14 years revenue has grown about 20% a year, earnings per share about 18%, and the number of shares outstanding has fallen 20% (buybacks mean each remaining share owns more of the business). Anyone who bought when he took over in 1999 at 20 cents has made 72 times their money. Second, valuation: the stock trades at about 8.5 times its expected 2027 operating profit (the "EV/EBITDA" multiple — roughly, what you pay for each dollar of yearly operating cash earnings, counting debt). If the company keeps executing, the authors think a business like this deserves 10–12 times, which — combined with profit growth — gets them to a fair value of $22 to $30 a share versus $14.50 today. There is also unpriced upside in PerioMonitor, a chairside gum-disease test Oral Science invented that gives results in minutes instead of sending a swab to a lab; it is already approved in the US and management is shopping it to a global partner.

The risks are honest ones. The biggest is a competitor called Accrufer, launched in early 2025 by a private company, Kye Pharmaceuticals — the first and only prescription oral iron in Canada. That distinction is structural, not cosmetic: because FeraMAX is legally classified as a "natural health product" rather than a prescription drug, provincial drug plans and many insurers simply cannot cover it, while Accrufer is eligible. So far Accrufer looks to be attracting new patients rather than stealing FeraMAX's, and FeraMAX still grew in 2025 — but the authors call it "the single largest watch-point." Beyond that: Thyconvi's launch is unproven, the newly bought Oral Science depends heavily on its founder and on one Swiss supplier that is itself going through a leadership change, and the stock is extremely thinly traded — a typical day sees only about 5,000 shares change hands, with just one analyst covering it. That thinness is a double edge, and the authors say so plainly: it is precisely why a business this good can be this cheap, but it also means you cannot build or exit a meaningful position quickly, and small news moves the price hard. This is a multi-year, patience-required holding, not a trade. Disclosure: the authors and Forterra own the shares, and have committed not to trade them for ten business days after publishing.

Key points & figures extracted from the public Polymath Investor post (article text in transcript.txt) for personal study. Not investment advice. © Polymath Investor / Robert Gignac / Forterra Investment Management for source material.